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Aims: To evaluate diabetic retinopathy (DR) data from across the SUSTAIN clinical trial
programme.
Materials and methods: The SUSTAIN clinical trial programme evaluated the efficacy and
safety of semaglutide, a glucagon-like peptide-1 analogue, for the treatment of type 2 diabetes
(T2D). In SUSTAIN 6, a 2-year, pre-approval cardiovascular outcomes trial, semaglutide was
associated with a significant increase in the risk of DR complications (DRC) vs placebo. DR data
from across the SUSTAIN trials were evaluated, and post hoc analyses of the SUSTAIN 6 data
were conducted. These included subgroup analyses to identify at-risk patients and a mediation
analysis with initial change in glycated haemoglobin (HbA1c; percentage-points at week 16) as
a covariate, to examine the role of the magnitude of reduction in HbA1c as an intermediate
factor affecting risk of DRC.
Results: There was no imbalance in DR adverse events across the SUSTAIN 1 to 5 and Japa-
nese trials. The majority of the effect with semaglutide vs placebo in SUSTAIN 6 may be attrib-
uted to the magnitude and rapidity of HbA1c reduction during the first 16 weeks of treatment
in patients who had pre-existing DR and poor glycaemic control at baseline, and who were
treated with insulin.
Conclusions: Early worsening of DR is a known phenomenon associated with the rapidity and
magnitude of improvement in glycaemic control with insulin; the DRC findings in SUSTAIN
6 are consistent with this. Guidance regarding the early worsening of DR is recommended with
insulin. Similar recommendations may be appropriate for semaglutide.
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1 | INTRODUCTION
Semaglutide is a glucagon-like peptide-1 (GLP-1) analogue, with an
extended half-life of ~1 week, that is in development for the treat-
ment of type 2 diabetes (T2D).1,2 The efficacy and safety of semaglu-
tide has been evaluated in the Semaglutide Unabated Sustainability in
Treatment of Type 2 Diabetes (SUSTAIN) clinical trial programme,
including five global trials (SUSTAIN 1–5), two Japanese trials and
one pre-approval cardiovascular (CV) outcomes trial (SUSTAIN 6), and
covers the continuum of T2D care. Semaglutide treatment led to sig-
nificant and sustained improvements in glycated haemoglobin
(HbA1c) and body weight vs placebo and active comparators across
the SUSTAIN programme.3–8 In SUSTAIN 6, semaglutide demon-
strated a significant 26% risk reduction for the primary composite CV
outcome vs placebo at 2 years.8 Microvascular complications were
evaluated as a secondary endpoint; a significantly lower risk of new
or worsening nephropathy was reported with semaglutide vs placebo
(hazard ratio [HR] 0.64, 95% confidence interval [CI] 0.46-0.88;
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P = .005); however, semaglutide was associated with a higher rate of
diabetic retinopathy complications (DRC) vs placebo (HR 1.76; 95%
CI 1.11-2.78; P = .02).8
Risk factors for the development and progression of diabetic reti-
nopathy (DR) include poor glycaemic control, long duration of diabe-
tes and poorly controlled blood pressure.9 The beneficial effect of
long-term, stringent glycaemic control on the prevention or delay in
onset or progression of DR in patients with type 1 diabetes and T2D
is established10–12; however, large and rapid improvements in glycae-
mic control may be associated with a transient worsening of DR,
which in the long term can be counterbalanced by reduction in DR
with improved glycaemia.11,13 Risk factors for DR are well recognized
and should be monitored and managed in accordance with existing
guidelines.14
In the present paper, we present how DR was evaluated, and the
results obtained, across the full clinical development programme for
semaglutide. Additionally, we present new analyses that provide fur-
ther insights into the DRC findings from SUSTAIN 6.
2 | MATERIALS AND METHODS
The SUSTAIN 1 to 5 and Japanese trials assessed the efficacy and
safety of subcutaneous, once-weekly semaglutide (0.5; 1.0 mg) vs
placebo or active comparators in adult populations with T2D, ranging
from treatment-naïve patients to those treated with insulin
(Table S1).3–8 In the SUSTAIN 1 to 5 and Japanese trials, known pro-
liferative retinopathy or maculopathy requiring acute treatment,
according to the opinion of the investigator, were exclusion criteria,
and the upper limit of HbA1c was 10% or 10.5%.
SUSTAIN 6 was a 2-year CV outcomes trial, designed to assess
the CV safety of once-weekly semaglutide (0.5; 1.0 mg) vs volume-
matched placebo, as an add-on to standard of care.8 The primary
comparison was pooled semaglutide vs pooled placebo. Secondary
microvascular outcomes included new or worsening nephropathy and
DRC, both based on external event adjudication committee (EAC)-
confirmed events. The trial enrolled 3297 patients who, in contrast to
the SUSTAIN 1 to 5 and Japanese trials, represented a population
with advanced T2D and high CV risk.8 Importantly, there were no
inclusion/exclusion criteria related to DR, and no upper limit for
HbA1c.
2.1 | Assessment of DR across the SUSTAIN clinical
trial programme
Data collection on DR (Table S2) included medical history, adverse
event (AE) reporting, EAC-confirmed DRC (SUSTAIN 6 only) and fun-
doscopy or fundus photography.
2.1.1 | Medical history
In the SUSTAIN 1 to 5 and Japanese trials, history of DR was col-
lected as part of the patient's medical history. In SUSTAIN 6, investi-
gators completed a diabetes complications form at baseline,
describing the patient's DR status by answering the following ques-
tions: Does the subject have DR (yes/no/unknown)? If yes, what type
of DR (non-proliferative/proliferative/unknown)? Has the patient had
any of the following: macular oedema, treatment with either laser
therapy/intravitreal agents, or surgery, eg, vitrectomy?
2.1.2 | Fundoscopy/fundus photography
Fundoscopy/fundus photography was performed in all SUSTAIN trials
at baseline, unless undertaken within 90 days prior to randomization.
In SUSTAIN 6, fundoscopy/fundus photography was also performed
at weeks 56 and 104 (planned end of treatment), or after premature
discontinuation of treatment, and in the Japanese trials it was also
performed at the planned end of treatment. Fundoscopy/fundus pho-
tography could be performed by the investigator, local ophthalmolo-
gist or optometrist according to local practice; however, no record of
who performed the examinations or the type of assessment per-
formed was kept. Furthermore, dilation of the pupil during these
assessments was not mandatory, and thus not recorded, and fundus
photographs were not centrally graded. Findings were categorized, as
per the protocol, by the investigator as “normal,” “abnormal, not clini-
cally significant,” or “abnormal, clinically significant.” Fundoscopic
data from SUSTAIN 1 to 5 and the Japanese trials are not presented.
2.1.3 | AE reporting
Diabetic retinopathy AEs were collected as part of the standard
safety reporting of AEs in all SUSTAIN clinical trials.
2.1.4 | EAC-confirmed DRC (SUSTAIN 6)
Time to first event of DRC was a secondary endpoint measured in
SUSTAIN 6 only. The endpoint was dichotomous (yes/no) and an
event of DRC was defined as the time from randomization to first
occurrence of one or more of the following: 1. need for retinal photo-
coagulation; 2. need for treatment with intravitreal agents; 3. vitreous
haemorrhage; and 4. onset of diabetes-related blindness, defined as a
Snellen visual acuity of 20/200 [6/60] or less, or a visual field of 20
or less, in the better eye with the best correction possible at the time
of the event.
Criteria were not mutually exclusive; simultaneous fulfilment of
more than one of the criteria was considered a single event for the
DRC endpoint.
Adjudication of DRC was performed by an external EAC, com-
prising two independent ophthalmologists, who were masked to
treatment (Supporting Information, File S1).
Further information was requested from the sites by Novo Nor-
disk after the trial completion regarding the EAC-confirmed blindness
cases.
2.2 | Statistical analysis
2.2.1 | SUSTAIN 1 to 5 and Japanese trials
Descriptive summaries of DR AEs were completed for the SUSTAIN
1 to 5 and Japanese trials.
2.2.2 | SUSTAIN 6
Post hoc subgroup analyses were conducted for time to first EAC-
confirmed DRC using unstratified Cox proportional hazards models,
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with an interaction between treatment (semaglutide, placebo) and
subgroup variable (Supporting Information, File S2) as fixed factors.
The impact of insulin use during the trial on the risk of DRC was
explored in an unstratified Cox proportional hazards model with an
interaction between treatment (semaglutide, placebo) and insulin use
during the trial as time-varying covariate (Supporting Information, File
S2). This analysis was carried out according to baseline DR (yes, no,
unknown/missing).
A post hoc mediation analysis was conducted to evaluate the
role that intermediate factors (mediators) play in describing the total
effect on DRC using an unstratified Cox proportional hazards model
that, in addition to treatment (semaglutide, placebo) as a fixed factor,
included the following: change in HbA1c at week 16 (nadir) as a
covariate, and baseline variables, HbA1c, DR (yes/no/unknown), and
duration of diabetes. This analysis was also expanded to include other
baseline variables (Supporting Information, File S2). A similar post hoc
mediation analysis was conducted including change in systolic blood
pressure (mm Hg) at week 16 as a covariate, as a substitute for
HbA1c (Supporting Information, File S2).
3 | RESULTS
3.1 | Baseline characteristics
The baseline characteristics of patients in SUSTAIN 1 to 5 and Japa-
nese trials vs SUSTAIN 6 are described in Table 1. The proportion of
patients with DR at baseline in the SUSTAIN 1 to 5 and Japanese tri-
als was 3.7% to 14.5%. In SUSTAIN 6, 29.4% of the trial population
had known, pre-existing DR at baseline (semaglutide, 30.9%; placebo,
27.8%), and there were similar numbers of patients with proliferative
DR at baseline in both treatment groups (semaglutide, 6.3%; placebo,
6.0%; Table S3).
3.2 | Diabetic retinopathy AEs
The DR AEs reported in the SUSTAIN 1 to 5 and Japanese trials were
balanced across treatments, all events were mild or moderate and
there were no serious AEs (Table 2). In SUSTAIN 6, a greater propor-
tion of AEs was reported in semaglutide- vs placebo-treated patients.
TABLE 1 Baseline characteristics across the SUSTAIN clinical trial programme
Mean (SD)
SUSTAIN 1
N = 387
SUSTAIN 2
N = 1225
SUSTAIN 3
N = 809
SUSTAIN 4
N = 1082
SUSTAIN 5
N = 396
JP SUSTAIN
MONO
N = 308
JP SUSTAIN
OAD
N = 601
SUSTAIN 6
N = 3297
Age, years 53.7 (11.3) 55.1 (10.0) 56.6 (10.7) 56.5 (10.4) 58.8 (10.1) 58.3 (10.7) 58.5 (10.3) 64.6 (7.4)
HbA1c, % 8.1 (0.9) 8.1 (0.9) 8.3 (1.0) 8.2 (0.9) 8.4 (0.8) 8.1 (0.9) 8.1 (0.9) 8.7 (1.5)
T2D duration, years 4.2 (5.5) 6.6 (5.1) 9.2 (6.3) 8.6 (6.3) 13.3 (7.8) 8.0 (6.3) 8.8 (6.4) 13.9 (8.1)
Systolic blood
pressure, mm Hg
128.8 (13.2) 132.6 (14.9) 133.5 (14.5) 132.1 (15.3) 134.8 (16.0) 129.1 (14.8) 129.2 (13.0) 135.6 (17.1)
Medical history of
DR, n (%)
15 (3.9) 94 (7.7) 30 (3.7) 50 (4.6) 55 (13.9) 42 (13.6) 87 (14.5) 969 (29.4)
Abbreviations: DR, diabetic retinopathy; JP, Japanese; MONO, monotherapy; OAD, oral antidiabetic drug; T2D, type 2 diabetes.
TABLE 2 Diabetic retinopathy adverse events with their respective investigator-assessed severity as reported across the SUSTAIN clinical trial
programme
SUSTAIN 1-5 and Japanese SUSTAIN trials
Semaglutide 0.5 mg
N = 1373
Semaglutide 1.0 mg
N = 1777
Comparators
N = 1657
n (%) E R n (%) E R n (%) E R
All events 32 (2.1) 35 2.6 30 (1.5) 36 1.9 31 (2.0) 31 2.1
Severe 0 0 0 0 0 0
Moderate 3 (0.2) 4 0.3 3 (0.2) 5 0.3 6 (0.4) 6 0.4
Mild 29 (1.9) 31 2.3 27 (1.3) 31 1.6 25 (1.6) 25 1.7
SAEs 0 0 0 0 0 0
SUSTAIN 6
Semaglutide 0.5 mg
N = 826
Semaglutide 1.0 mg
N = 822
Placebo
N = 1649
n (%) E R n (%) E R n (%) E R
All events 74 (9.0) 86 5.0 82 (10.0) 99 5.8 125 (7.6) 145 4.3
Severe 5 (0.6) 6 0.4 5 (0.6) 5 0.3 7 (0.4) 7 0.2
Moderate 27 (3.3) 33 1.9 22 (2.7) 25 1.5 35 (2.1) 37 1.1
Mild 44 (5.3) 47 2.8 57 (6.9) 69 4.1 86 (5.2) 101 3.0
SAEs 6 (0.7) 7 0.4 5 (0.6) 6 0.4 8 (0.5) 8 0.2
Abbreviations: E, events; R, events per 100 patient-years of observation; SAE, serious adverse event. Proportions for SUSTAIN 1 to 5 and Japanese SUS-
TAIN trials are adjusted proportions. Mild, no or transient symptoms, no interference with the subject's daily activities; moderate, marked symptoms,
moderate interference with the subject's daily activities; severe, considerable interference with the subject's daily activities; unacceptable.
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The majority of AEs were mild or moderate; few were reported as
serious AEs (Table 2).
3.3 | DRC in SUSTAIN 6
More patients treated with semaglutide (50 [3.0%]) vs placebo
(29 [1.8%]) experienced EAC-confirmed DRC;8 more adjudicated
events were confirmed with semaglutide vs placebo for all four com-
ponents of the DRC endpoint (Table S4). Although 79 patients had
DRC, there were 98 events in total, as some patients had more than
one event (Supporting Information, File S1 and Table S4).
3.3.1 | Baseline characteristics of patients with DRC
Compared with the overall trial population, patients with EAC-
confirmed DRC were characterized by pre-existing DR, a longer mean
diabetes duration, higher mean HbA1c levels at baseline and greater
proportions of patients receiving insulin treatment at trial entry
(Table S3).
A greater proportion of patients with DRC had pre-existing DR
at baseline vs the overall trial population (66 [83.5%] vs 969 [29.4%],
respectively; 23 [29.1%] vs 202 [6.1%] with proliferative DR, and
14 [17.7%] vs 112 [3.4%] of these had received laser therapy or
treatment with intravitreal agents prior to enrolment, respectively).
The proportions of patients were similar in each treatment arm
(42 [84.0%] and 24 [82.8%] for semaglutide and placebo, respec-
tively; Table S3 and Figure 1A). For semaglutide-treated patients with
no known pre-existing DR at baseline, the risk of DRC was low and
there was no statistically significant difference vs placebo (Table S3
and Figure 1B); the number (proportion) of patients with no pre-
existing DR at baseline who developed an event was 5 (10.0%) for
semaglutide and 4 (13.8%) for placebo. Overall, a higher risk for DRC
with semaglutide vs placebo was observed in patients with prolifera-
tive and non-proliferative DR at baseline (Figure S1). There was no
evidence of a dose-dependent effect on DRC with semaglutide (Fig-
ure S2): 25 patients in each dose group had an event.
In patients with pre-existing DR at baseline, the risk of DRC was
further increased in patients treated with insulin prior to the event
(Figure 1C,D). No increase in risk was associated with prior insulin
use in patients without known pre-existing DR at baseline.
3.3.2 | Glycaemic control
Semaglutide-treated patients experienced significant and sustained
reductions in HbA1c from baseline vs placebo in the overall trial pop-
ulation (Figure 2A,B).8 The reduction in HbA1c with semaglutide vs
placebo in patients with DRC was 1.9% and 2.5% at week 16 with
semaglutide 0.5 and 1.0 mg, respectively, vs 0.9% and 1.3% with pla-
cebo 0.5 and 1.0 mg (Figure 2C) and reductions in HbA1c were
greater vs the overall trial population until the end of the trial (week
104, Figure 2D). A similar pattern for the incidence rate of DRC with
semaglutide or placebo was seen in patients with pre-existing DR,
when stratified according to change in HbA1c by week 16. The inci-
dence rate of confirmed events was highest in patients with HbA1c
reductions >1.5% with semaglutide or placebo (Figure 3). In patients
without pre-existing DR, the incidence rate of DRC was low and
similar between treatment groups, regardless of the magnitude of
HbA1c reduction (Figure 3A).
A post hoc mediation analysis showed that when controlling for
HbA1c reduction at week 16, for semaglutide vs placebo, the HR for
DRC is reduced to 1.22 (95% CI 0.71-2.09; P = .48; Figure 2E); there-
fore, the majority of the treatment effect could be attributed to the
reduction in HbA1c at week 16. Expansion of the mediation analysis
to include other baseline variables did not change the mediator analy-
sis results (Supporting Information, File S3).
3.3.3 | Blood pressure control
Additional post hoc analyses were performed to assess the role of
blood pressure control in the DRC finding; however, there was no
indication of an effect (Supporting Information, File S3).
3.4 | Events evaluated as diabetes-related blindness
in SUSTAIN 6
In total, the EAC evaluated that 6 patients met the criteria for events
of diabetes-related blindness: 5 with semaglutide; 1 with placebo
(Table S5). All 5 semaglutide-treated patients had pre-existing prolif-
erative DR and other eye diseases (eg, cataract), and all had received
treatment with laser therapy and/or intravitreal agents prior to enter-
ing the trial. The placebo-treated patient with diabetes-related blind-
ness had no known pre-existing DR.
Further information was available for 3 of the 5 semaglutide-
treated patients post event, none of whom continued to fulfill the cri-
teria for diabetes-related blindness (2 patients 18 months post event,
and 1 patient, 21 days post event).
3.5 | Fundoscopy/fundus photographs in
SUSTAIN 6
Table S6 shows fundoscopy/fundus photograph assessments at base-
line and end of treatment. After 2 years, the proportion of patients in
each category was similar in the two treatment arms.
4 | DISCUSSION
The SUSTAIN clinical trial programme was designed to evaluate the
efficacy and safety of semaglutide across the continuum in patients
with T2D; the trials were not specifically designed to investigate
DR. Although there was no increase in DR AEs in the SUSTAIN 1 to
5 or Japanese trials with semaglutide vs comparators, there was a sig-
nificant 76% increase in the risk of DRC with semaglutide vs placebo
in SUSTAIN 6.8
The increased risk of DRC in SUSTAIN 6 was identified using a
dichotomous secondary endpoint, thus only allowing the identifica-
tion of predetermined events, and the trial design does not provide a
sensitive assessment of progression of retinal changes over time. Fur-
thermore, clinical interpretation of the DRC results is challenging for
several reasons: the endpoint is a mixture of treatments and diagno-
ses, it does not take into account pre-existing eye disease and there
was no routine assessment of visual acuity. Lastly, as the severity of
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FIGURE 1 Kaplan–Meier plots showing
time to first event adjudication committee
(EAC)-confirmed diabetic retinopathy
complications (DRC) in SUSTAIN 6 by:
baseline diabetic retinopathy (DR) status,
yes (A), no (B); in patients with DR at
baseline with insulin use prior to event,
yes (C), no (D). The proportion of patients
with events with “unknown” status of DR
at baseline was 3 for semaglutide and
1 for placebo (hazard ratio [HR] 2.73; 95%
confidence interval [CI] 0.28−26.26); the
proportion of patients with events with
“unknown” status of DR at baseline with
insulin use “yes” was 1 for semaglutide
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DR was not formally assessed at baseline nor graded during the trial,
any potential changes in DR severity cannot be determined from the
data collected in SUSTAIN 6.
Semaglutide treatment in SUSTAIN 6 led to more pronounced
reductions in HbA1c vs placebo;8 the difference occurred despite
investigators being masked to treatment assignment and encouraged
throughout the trial to actively treat hyperglycaemia by adding
antihyperglycaemic agents as per local guidelines. A post hoc media-
tion analysis suggests that the increase in DRC seen with semaglutide
vs placebo may be associated with the large and rapid decline in
HbA1c during the first 16 weeks of treatment. Furthermore, the
majority of patients with DRC events were treated with insulin prior
to, or at the time of, the event. While no data are available to support
an interaction with insulin, use of insulin therapy appears to identify
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FIGURE 2 Glycated haemoglobin (HbA1c) in SUSTAIN 6: Change in HbA1c over time and from baseline to week 104 in the overall population
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the effect of change in HbA1c at week 16 on time to first DRC. This is analysed by an unstratified Cox proportional hazards model, which in
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confounders were “gender” and “body weight” at baseline. Missing values of HbA1c were imputed as predicted values from a mixed model for
repeated measurements. “Proportion eliminated” is calculated as: (total effect of treatment − controlled direct effect of treatment)/(total effect
of treatment −1); ie, the absolute risk reduction from the mediation analysis divided by the total excess risk. Panel A is from Marso SP, Bain SC,
Consoli A. et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 375(19):1834–1844. Copyright ©
(2016) Massachusetts Medical Society. Reprinted with permission. CI, confidence interval; HR, hazard ratio
6 VILSBØLL ET AL.
those patients at highest risk of DRC, and includes those with known
risk factors for DR, including longer duration of diabetes and high
baseline HbA1c. The combination of pre-existing DR and insulin use
may be important, therefore, for identifying the patients at the high-
est risk of developing DRC. Importantly, there was no increase in risk
of DRC with semaglutide vs placebo in patients without pre-existing
DR, regardless of whether they were receiving insulin treatment.
Rapid and marked reductions in HbA1c, as a result of improved
glycaemic control initiated during pregnancy, bariatric surgery or
intensified insulin treatment, have previously been associated with
transitory worsening of DR11,12,15–19; this has also been reported in
patients with type 1 diabetes in the Diabetes Control and Complica-
tions Trial (DCCT),12 and in newly diagnosed patients with T2D in the
UK Prospective Diabetes Study (UKPDS 33).11 It is important to note
that the DCCT excluded patients with proliferative retinopathy, and
used a more sensitive assessment method with graded retinal imaging
to chart the progression of DR.12 Although the characteristics of
patients in the DCCT are different from those in SUSTAIN 6, the
increased risk of DRC may be a manifestation of an “early worsening”
phenomenon attributable to the large and rapid reduction in HbA1c.
Consequently, patient profiling and risk assessment before intensifi-
cation of treatment may help identify patients whose eyes require
close monitoring.
Other agents causing abrupt glycaemic improvement (eg, insulin)
have warnings in their prescribing information about the potential
association with temporary worsening of DR.20 In the insulin glargine
clinical development programme, more frequent DR progression was
reported with insulin glargine vs NPH in patients with T2D;21 how-
ever, a subsequent 5-year DR trial, employing 7-field Early Treatment
Diabetic Retinopathy Study fundus photographic assessment, showed
no detrimental effect with insulin glargine vs NPH on the long-term
progression of DR.22
As a CV outcomes trial, SUSTAIN 6 was, by design, different
from other SUSTAIN trials, and indeed from other phase III develop-
ment programmes. These differences relate to the inclusion of
patients with pre-existing advanced DR requiring acute treatment in
SUSTAIN 6. Additionally, patients were older, had a higher baseline
HbA1c and a longer duration of diabetes, and a higher proportion
had pre-existing DR vs those included in the other SUSTAIN trials. All
of these factors increased the overall risk of DR in the SUSTAIN
6 population.
Limited data are available regarding DR with GLP-1 receptor ago-
nists. In the LEADER trial, the CV outcomes trial of liraglutide, the HR
for the DRC endpoint disfavoured liraglutide, although the difference
was not significant (HR 1.15; 95% CI 0.87-1.52; P = .33).23 With exe-
natide, a retrospective analysis of patients receiving treatment twice
daily for longer than 6 months, showed that DR had progressed in
30% of patients and progression of DR was associated with greater
reductions in HbA1c; there was no comparator.24 In the same group
of patients, DR had improved or remained stable after follow-up, sug-
gesting that early worsening did not progress.25 With albiglutide, a
higher incidence of on-therapy DR AEs was reported vs placebo
(3.6% vs 1.7%), but not with comparators.26 Importantly, only one of
these studies applied robust methods for assessing DR prospec-
tively25; whereas the majority of the DR findings relating to GLP-1
receptor agonists were based on standard AE reporting and not reti-
nal imaging. The patient populations and the inclusion/exclusion cri-
teria differ across the clinical development programmes, making
clinical interpretation difficult.
Although the DRC data in SUSTAIN 6 are consistent with an
early worsening phenomenon secondary to glycaemic improvement
in patients with pre-existing DR, it is important to consider alterna-
tive aetiologies. Animal toxicology studies with semaglutide and lira-
glutide in non-diabetic animals have shown no evidence for a direct
GLP-1 receptor agonist effect on the retina, and semaglutide data
have shown no treatment-related changes (including DR) in the eyes
of any of the species studied.27
The increased risk of DRC with semaglutide vs placebo in
patients with poor glycaemic control and pre-existing DR in SUSTAIN
6 must be viewed in the wider context of the overall benefits with
semaglutide treatment, including reduction in HbA1c, body weight
and CV risk reduction.8
The beneficial effect of intensive glycaemic control on microvas-
cular outcomes in the long term is well described, and optimization of
0
2
4
6
8
10
12
<0.5 0.5–1.5 >1.5 <0.5 0.5–1.5 >1.5 <0.5 0.5–1.5 >1.5
0
2
4
6
8
10
12
<0.5 0.5–1.5 >1.5
(B)(A)
In
ci
d
en
ce
 r
at
e 
o
f 
fi
rs
t 
ev
en
ts
 p
er
 1
00
 P
Y
R
HbA1c reduction at Week 16
Patients with 
event/at risk 2/658 2/291 0/140 0/131 2/399 3/493 9/245 7/138 8/76 4/61 15/213 23/236
HbA1c reduction at Week 16
Placebo PlaceboSemaglutide Semaglutide
FIGURE 3 Incidence of diabetic retinopathy complications (DRC) in SUSTAIN 6 by baseline diabetic retinopathy (DR) and glycated haemoglobin
(HbA1c) reduction: patients without baseline DR (A); patients with known pre-existing DR (B). Values are observed incidence rates per
100 patient-years of risk (PYR) with error bars representing 95% confidence intervals (CIs). A patient's risk time is defined as the time from
randomization to first event or censoring
VILSBØLL ET AL. 7
glycaemic control remains the cornerstone of diabetes management
and the prevention, or prevention of progression, of microvascular
diseases such as DR and nephropathy. Improved glycaemic control
had a beneficial effect on DR in both the DCCT and the UKPDS in
the long term, and the magnitude of benefit on the risk of DR contin-
ued to increase over time, and was more pronounced in patients with
DR at baseline.11,12
Although fundoscopic assessments were collected in SUSTAIN
6, there are significant limitations to the granularity of these data,
and it is necessary to interpret them with caution. However, they do
provide reassurance that the retinal changes observed with semaglu-
tide are similar to those seen with placebo at the end of treatment.
Furthermore, events that the EAC evaluated as “onset of diabetes-
related blindness” were not annulled if blindness resolved spontane-
ously or as a result of treatment, as occurred in all 3 patients for
whom further information was available, out of the 5 semaglutide-
treated patients. In this context, it is important to note that there are
further limitations associated with the collection of the DRC data: the
definition of onset of diabetes-related blindness did not exclude
other sight-threatening conditions and visual acuity was only
recorded once at the time of the event. Regarding vitreous haemor-
rhage, no data are available on duration or severity.
In conclusion, an increase in DRC was observed in SUSTAIN 6 in
high-risk patients, and the data are consistent with the phenomenon
of early worsening of pre-existing DR, secondary to an initial, rapid
improvement in glycaemic control. This conclusion is supported by a
post hoc mediation analysis, which suggests that the DRC finding in
SUSTAIN 6 is seen in patients with pre-existing DR and is primarily
attributable to the magnitude and rapidity of reduction in HbA1c dur-
ing the first 16 weeks of the trial. Additionally, there was no evidence
for an increase in DR AE reporting in the SUSTAIN 1 to 5 or Japa-
nese trials with semaglutide vs comparators. While further clinical
evidence is required to understand fully the impact of semaglutide in
general and on the progression of DR, it should be noted that physi-
cians are alerted to the risk of worsening DR associated with intensi-
fied treatment in the prescribing information for insulins; similar
recommendations may be appropriate when initiating other effica-
cious treatments, such as semaglutide.
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